Marburg is an Ebola-like virus suitable for weaponization by hostile forces. Working directly with the United States Department of Defense, we are developing FlowVax Marburg, a prophylactic nebulized biomedicine to protect at-risk military forces and civilians.
FlowVax Marburg Vaccine Development is funded by the United States Department of Defense Chemical and Biological Defense Program.
Most vaccines are designed to generate an antibody response. Our FlowVax peptide vaccine platform is being designed to induce T-cells to attack viruses and cancer markers expressed on the surface of the patient’s cells. We believe that Flow Pharma’s Artificial Intelligence (“AI”) augmented techniques can enable us to find the most susceptible sites on the Marburg virus for attack by the patient’s immune system.
Overview
- Under Development, FDA Approval Required.
- Marburg Virus could be deployed as a weapon of war against the United States.
- Marburg Vaccine Development is funded by the United States Department of Defense Chemical and Biological Defense Program.
- Delivery by inhalation.
- Non-human primate study in progress (Winter 2021).
Current Status
-
Phase I STTR
-
Phase II STTR & Pre-Clinical Trial
-
Phase I Clinical Trial
What is Marburg?
Marburg virus is a a Category A Bioterrorism Agent according to the Centers for Disease Control. Marburg virus (MARV) causes Marburg virus disease in humans and nonhuman primates, a form of viral hemorrhagic fever. The virus is considered to be extremely dangerous.
Colorized scanning electron micrograph of Marburg virus particles (blue) both budding and attached to the surface of infected VERO E6 cells (orange). Image captured and color-enhanced at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID